- Home
- ITRM vs IGC Comparison
ITRM vs IGC Comparison
Compare ITRM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRM | IGC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 28.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ITRM | IGC |
|---|---|---|
| Price | $0.34 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $4.13 |
| AVG Volume (30 Days) | ★ 968.4K | 444.0K |
| Earning Date | 03-20-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $390,000.00 | ★ $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | $193.01 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.26 | $0.25 |
| 52 Week High | $1.75 | $0.50 |
Technical Indicators
Market Signals| Indicator | ITRM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 43.82 |
| Support Level | $0.31 | $0.29 |
| Resistance Level | $0.39 | $0.31 |
| Average True Range (ATR) | 0.03 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.84 | 25.71 |
Price Performance
Historical ComparisonAbout ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.